Patents Examined by Yunsoo Kim
  • Patent number: 11655289
    Abstract: Pharmaceutical compositions containing anti-beta amyloid (A?) antibodies or AD-binding fragments thereof are provided. These pharmaceutical compositions find use in the treatment of abnormal accumulation or deposition of A? in the central nervous system, mild cognitive impairment, and AD-associated disorders such as Alzheimer's disease.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 23, 2023
    Assignee: Biogen MA Inc.
    Inventors: Steven Andrew Lantz, Kapil Gupta, Shantanu Sule, Adnan Zunic
  • Patent number: 11648317
    Abstract: The disclosure provides stable pharmaceutical compositions comprising an anti-CD79b immunoconjugate and a surfactant. The disclosure also provides methods for using such compositions for the treatment of cancer.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: May 16, 2023
    Assignee: Genentech, Inc.
    Inventors: Ankit R. Patel, Jun Liu
  • Patent number: 11639391
    Abstract: The present invention provides a stable liquid formulation of an antibody in phosphate-amino acid based dual buffer system. The antibody formulated in phosphate-amino acid based dual buffer system imparts optimum stability to the antibody, at lower as well as higher concentrations. Further, the antibody formulated in phosphate-amino acid based buffer system has low viscosity and is suitable for therapeutic administration of high concentrations of antibody.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: May 2, 2023
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Murali Jayaraman, Pravin Nair, Navneet Kaur, Deepak Thumbrahalli
  • Patent number: 11634485
    Abstract: Stable aqueous pharmaceutical formulations for therapeutic antibodies and methods of using such stable aqueous pharmaceutical formulations.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 25, 2023
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Karthik Pisupati
  • Patent number: 11628217
    Abstract: The present invention relates to stable, high-concentration low-viscosity formulations of MASP-2 inhibitory antibodies, kits comprising the formulations and therapeutic methods using the formulations and kits for inhibiting the adverse effects of MASP-2 dependent complement activation.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 18, 2023
    Assignee: OMEROS CORPORATION
    Inventors: Gregory A. Demopulos, Kenneth M. Ferguson, William Joseph Lambert, John Steven Whitaker
  • Patent number: 11612562
    Abstract: An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. The present inventors discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid as a counter ion species in histidine buffer or tris(hydroxymethyl)aminomethane, specifically by using histidine-aspartate buffer or histidine-glutamate buffer, or tris(hydroxymethyl)aminomethane-aspartate or tris(hydroxymethyl)aminomethane-glutamate as a buffer. The present inventors also discovered that a significant stabilization effect was achieved by using an acidic amino acid, aspartic acid or glutamic acid, as a counter ion species to a basic amino acid such as arginine, specifically by using arginine-aspartate or arginine-glutamate.
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: March 28, 2023
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Chifumi Moriyama
  • Patent number: 11613570
    Abstract: The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule. This invention also provides for a pre-filled syringe for carrying out the above-described method.
    Type: Grant
    Filed: April 14, 2022
    Date of Patent: March 28, 2023
    Assignee: 180 THERAPEUTICS LP
    Inventors: Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
  • Patent number: 11608357
    Abstract: There is provided, inter alia, an aqueous solution comprising (i) an antibody protein; and (ii) a antibody protein stabilizing mixture of arginine, methionine, and a C3 polyol.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: March 21, 2023
    Assignee: ARECOR LIMITED
    Inventors: Jan Jezek, Luca Badiali, David Gerring
  • Patent number: 11603407
    Abstract: The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: March 14, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Qingyan Hu, Dingjiang Liu
  • Patent number: 11596690
    Abstract: The present invention provides pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-33 (hIL-33). The formulations may contain, in addition to an anti-IL-33 antibody, a buffer, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months and after being subjected to thermal and other physical stresses.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 7, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Qingyan Hu, Dingjiang Liu
  • Patent number: 11590243
    Abstract: The present invention relates to the formulation of adenoviral vectors in sorbitol containing compositions in combination with a further amorphous sugar, its formulation as well as a method for obtaining a dried composition.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 28, 2023
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Erwan Bourles, Olivier Despas, Delphine Guillaume, Frederic Mathot, Mathieu Vasselle
  • Patent number: 11583584
    Abstract: The present invention is directed to compositions and methods for stabilizing a protein without a surfactant. The present invention is further directed to compositions comprising a protein and at least one excipient selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, low molecular weight aliphatic polyacids, zwitterions, phospholipids, cyclodextrins, polyethylene glycols, gelatins, urea, ethanol, glycerin, dextran, xanthan gum, 2-(2-ethoxyethoxy)ethanol, hydroxypropyl cellulose, propylene glycol, a short-chain organic acid, deoxycholate, sodium nitrate, sodium sulfate, proline and lysine.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 21, 2023
    Assignee: Coherus Biosciences, Inc.
    Inventors: Jun Liu, Mark Manning, Isaias Prado
  • Patent number: 11576863
    Abstract: The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention also relates to the reconstituted formulation obtained by the method described herein, the use of said antibody formulation as a medicament, the use of the lyophilized formulation for the preparation of a medicament and a method of treating a patient.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 14, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Markus Rast, Wolfgang Ise, Gerhard Becker, Peter Skufca, Henning Gieseler
  • Patent number: 11576970
    Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 14, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Andrew Jeffrey Yates, James Gregory Clipstone
  • Patent number: 11571383
    Abstract: Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: February 7, 2023
    Assignee: CytoDyn Inc.
    Inventor: Tracy T. Chen
  • Patent number: 11560434
    Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: January 24, 2023
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown
  • Patent number: 11547740
    Abstract: Embodiments of the invention employ methods and compositions for enhancing potency of immune cells that express one or more therapeutic proteins. In certain cases, the methods modulate expression of a CAR transgene in an immune cell, such as a T cell. Specific embodiments employ the exposure of cells and/or individuals to be treated with the cells with an effective amount of at least one agent that upregulates expression of the therapeutic protein, such as a mitogen, histone deacetylase inhibitor, and or DNA methyltransferase inhibitor.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: January 10, 2023
    Assignee: Baylor College of Medicine
    Inventors: Juan Fernando Vera Valdes, Malcolm Brenner, Usanarat Anurathapan
  • Patent number: 11498961
    Abstract: A pharmaceutical composition containing an SOST antibody or an antigen-binding fragment thereof in an acetic acid-sodium acetate buffer solution is described. In addition, the pharmaceutical composition can also contain sugar, a nonionic surfactant or other excipients. After being stored for several months, the pharmaceutical composition exhibits good antibody stability.
    Type: Grant
    Filed: July 26, 2018
    Date of Patent: November 15, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jingjing Fang, Zhen Yan, Xun Liu
  • Patent number: 11491111
    Abstract: The present invention relates generally to the field of immunogenic compositions containing volatile salts. In certain embodiments, compositions and methods disclosed herein relate to producing and using novel combinations to create frozen immunogenic agents bound to adjuvant having improved formulations and improved consistency of distribution of adjuvant for storage and subsequent delivery to a subject in need thereof.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: November 8, 2022
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Kimberly Hassett, Pradyot Nandi, John Carpenter, Theodore Randolph
  • Patent number: 11491239
    Abstract: Provided herein are engineered non-catalytic, non-toxic tetanus toxin variants and methods of using such engineered tetanus toxin variants as low dose, protective vaccines that are non-toxic and more potent than their respective chemically inactivated toxoids. In addition, provided herein are conjugate vaccine carriers comprising engineered tetanus toxin variants and methods of using such conjugate vaccines to elicit T-cell dependent immune memory responses which can target a broad spectrum of microbial pathogens as a single vaccine.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: November 8, 2022
    Assignees: The Medical College of Wisconsin, Inc., Wisconsin Alumni Research Foundation
    Inventors: Joseph T. Barbieri, Eric A. Johnson, Sabine Pellett, William H. Tepp, Amanda Przedpelski